176.93
Schlusskurs vom Vortag:
$177.10
Offen:
$177.145
24-Stunden-Volumen:
740.29K
Relative Volume:
0.69
Marktkapitalisierung:
$8.69B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
22.09
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+14.53%
1M Leistung:
+17.79%
6M Leistung:
+7.25%
1J Leistung:
-20.23%
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CRL
Charles River Laboratories International Inc
|
176.93 | 8.70B | 4.06B | 413.08M | 560.48M | 8.01 |
![]()
TMO
Thermo Fisher Scientific Inc
|
478.32 | 179.32B | 43.21B | 6.58B | 6.17B | 17.29 |
![]()
DHR
Danaher Corp
|
205.48 | 145.22B | 24.01B | 3.41B | 4.86B | 4.70 |
![]()
IDXX
Idexx Laboratories Inc
|
565.19 | 44.23B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
IQV
Iqvia Holdings Inc
|
199.17 | 34.14B | 15.50B | 1.33B | 2.16B | 7.34 |
![]()
A
Agilent Technologies Inc
|
120.18 | 34.19B | 6.63B | 1.17B | 1.19B | 4.05 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
2025-01-17 | Herabstufung | UBS | Buy → Neutral |
2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
2024-10-23 | Eingeleitet | CLSA | Underperform |
2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2024-06-28 | Herabstufung | Argus | Buy → Hold |
2024-06-07 | Eingeleitet | Mizuho | Neutral |
2024-06-06 | Eingeleitet | Goldman | Buy |
2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-05-24 | Eingeleitet | Guggenheim | Neutral |
2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
2022-04-07 | Eingeleitet | Stephens | Overweight |
2022-02-17 | Bestätigt | BofA Securities | Buy |
2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
2022-02-17 | Bestätigt | Deutsche Bank | Buy |
2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
2022-02-17 | Bestätigt | UBS | Buy |
2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
2020-05-13 | Hochstufung | UBS | Neutral → Buy |
2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
2020-01-07 | Eingeleitet | Citigroup | Buy |
2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
2018-10-09 | Eingeleitet | UBS | Neutral |
2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
How strong is Charles River Laboratories International Inc. company’s balance sheetTriple-digit returns - jammulinksnews.com
What are Charles River Laboratories International Inc. company’s key revenue driversSky-high profits - jammulinksnews.com
Is Charles River Laboratories International Inc. a growth stock or a value stockUnlock your portfolio’s hidden potential - jammulinksnews.com
What institutional investors are buying Charles River Laboratories International Inc. stockRapid wealth creation - jammulinksnews.com
Is Charles River Laboratories International Inc. a Top Dividend Stock to Watch in 2025Low Risk High Reward Picks - Metal.it
What catalysts could drive Charles River Laboratories International Inc. stock higher in 2025Breakout stock performance - jammulinksnews.com
How Charles River Laboratories International Inc. stock reacts to Fed policy changesSmart Money Trade Setups - Metal.it
How does Charles River Laboratories International Inc. compare to its industry peersGrow your wealth steadily and securely - jammulinksnews.com
What analysts say about Charles River Laboratories International Inc. stockFree Real-Time Stock Data - PrintWeekIndia
What drives Charles River Laboratories International Inc. stock priceExplosive trading opportunities - PrintWeekIndia
Is Charles River Laboratories International Inc. a good long term investmentHigh-profit capital plays - PrintWeekIndia
Charles River Laboratories International Inc. Stock Analysis and ForecastHigh-yield investments - Autocar Professional
Charles River Laboratories Surges 134.22% in Trading Volume, Ranks 365th in Daily Market - AInvest
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On ThursdayArrive AI (NASDAQ:ARAI), ASGN (NYSE:ASGN) - Benzinga
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development - StreetInsider
Charles River Labs Stock Rises on Plasmid DNA Deal with Ellys TeamNews and Statistics - IndexBox
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance
Why Are Charles River Laboratories (CRL) Shares Soaring Today | Markets | American Financial Group, Inc. - FinancialContent
Charles River Laboratories Surged 8.6% Intraday—Is This a Game-Changer for Biotech Innovation? - AInvest
Here's What to Expect From Charles River Laboratories' Next Earnings Report - MSN
Is it Prudent to Retain Charles River Stock in Your Portfolio Now? - MSN
Agree To Purchase Charles River Laboratories International At $150, Earn 21.4% Annualized Using Options - Nasdaq
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):